Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype C<i>gag</i>Vaccine in Healthy HIV-1-Uninfected Adults
Margaret Wecker, Donald S. Burke(University of Pittsburgh), Michael Pensiero(National Institute of Allergy and Infectious Diseases), Jeffrey D. Chulay(Research Triangle Park Foundation), Nina D. Russell(New York Blood Center), Peter B. Gilbert(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ya-Lin Chiu(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Salim S. Abdool Karim(Centre for the AIDS Programme of Research in South Africa), Mary Allen(National Institutes of Health)
Cited by 68
Related Papers
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
|The Lancet|2008|708
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
|New England Journal of Medicine|2013|586